Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Abdominal Cancer
66%
Fluorouracil
65%
Malignant Neoplasm
54%
Gemcitabine
53%
Cisplatin
41%
Folinic Acid
40%
Pancreas Cancer
40%
Biliary Tract Cancer
40%
Irinotecan
38%
Neoplasm
37%
Oxaliplatin
34%
Progression Free Survival
33%
First-Line Chemotherapy
33%
Disease
32%
Docetaxel
32%
Non Small Cell Lung Cancer
26%
Rectum Cancer
22%
Anthracycline
20%
Placebo
20%
Breast Cancer
20%
Metastatic Colorectal Cancer
20%
Colon Carcinoma
18%
Phase II Trials
18%
Adenocarcinoma
18%
Survival Rate
17%
Anemia
16%
Capecitabine
16%
Taxane
15%
Monotherapy
15%
Neutropenia
14%
Tamoxifen
13%
Janus Kinase 2
13%
Myeloproliferative Disorder
13%
Procedural Pain
13%
Lorazepam
13%
Catenin
13%
Survivin
13%
Angioimmunoblastic T Cell Lymphoma
13%
Cancer of Unknown Primary Site
13%
CA 19-9 Antigen
13%
Lung Cancer
13%
Metastatic Breast Cancer
13%
Clinical Feature
13%
Chronic Myeloid Leukemia
13%
Liver Cell Carcinoma
13%
Placebo-Controlled Study
13%
Hepatotoxicity
13%
Mitomycin
13%
Thalidomide
13%
Medicine and Dentistry
Overall Survival
84%
Progression Free Survival
43%
Disease
42%
Chemoradiotherapy
41%
Malignant Neoplasm
40%
Abdominal Cancer
40%
Attitude
38%
Life Sustaining Treatment
33%
First-Line Chemotherapy
32%
Hazard Ratio
30%
Cisplatin
29%
Radiation Therapy
29%
Fluorouracil
28%
Pancreas Cancer
28%
Adjuvant Radiotherapy
26%
Biliary Tract Cancer
26%
Janus Kinase 2
26%
Gemcitabine
26%
Recurrent Disease
24%
Prognostic Factor
23%
Survival Rate
22%
Rectum Cancer
22%
T Cell
22%
Adenocarcinoma
20%
Diagnosis
20%
Bile Duct Cancer
20%
Extrahepatic Bile Duct
20%
Advance Care Planning
20%
Arm
16%
Anemia
16%
Clinical Feature
16%
Neoplasm
16%
Mucosa-Associated Lymphoid Tissue
14%
Cross Sectional Study
14%
Population
14%
Low Drug Dose
13%
Survivin
13%
Rare Disease
13%
Assisted Suicide
13%
Advanced Cancer
13%
Cholangiocarcinoma
13%
Germinoma
13%
Adult T-Cell Leukemia/Lymphoma
13%
Placebo-Controlled Study
13%
Wernicke's Encephalopathy
13%
Myeloproliferative Disorder
13%
Angioimmunoblastic T-Cell Lymphoma
13%
Endodermal Sinus Tumor
13%
Pancreaticoduodenectomy
13%
CA 19-9 Antigen
13%
Nursing and Health Professions
Life Sustaining Treatment
30%
Advance Care Planning
26%
Advanced Cancer
26%
Hospice Care
17%
Radiotherapy
16%
Treatment Outcome
15%
Disease
14%
Clinical Feature
13%
Resuscitation
13%
Adjuvant Radiotherapy
13%
Cancer of Unknown Primary Site
13%
Adenocarcinoma
13%
Passive Euthanasia
13%
Active Euthanasia
13%
Von Willebrand Factor
13%
Von Willebrand Disease
13%
Angioimmunoblastic T Cell Lymphoma
13%
Teaching Hospital
13%
Bile Duct Cancer
13%
Blood Clotting Factor 8
13%
Overall Survival
12%
Confidence Interval
11%
Hazard Ratio
11%
Survival Rate
10%
Neoplasm
7%
Diagnosis
6%
Polymer
6%
Haemophilia A
6%
Rectum Cancer
6%
Bleeding Tendency
6%
Chemoradiotherapy
6%
Neoadjuvant Therapy
6%
Malignant Neoplasm
6%
Local Recurrence Free Survival
5%
Palliative Therapy
5%
Surgery
5%